KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Gross Margin (2019 - 2025)

Historic Gross Margin for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to 52.71%.

  • Esperion Therapeutics' Gross Margin fell 138100.0% to 52.71% in Q3 2025 from the same period last year, while for Sep 2025 it was 58.2%, marking a year-over-year decrease of 233800.0%. This contributed to the annual value of 79.36% for FY2024, which is 165500.0% up from last year.
  • Esperion Therapeutics' Gross Margin amounted to 52.71% in Q3 2025, which was down 138100.0% from 65.35% recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Gross Margin ranged from a high of 95.57% in Q2 2021 and a low of 51.3% during Q2 2022
  • For the 5-year period, Esperion Therapeutics' Gross Margin averaged around 67.38%, with its median value being 65.35% (2025).
  • In the last 5 years, Esperion Therapeutics' Gross Margin tumbled by -442800bps in 2022 and then soared by 405800bps in 2024.
  • Esperion Therapeutics' Gross Margin (Quarter) stood at 67.05% in 2021, then grew by 16bps to 77.89% in 2022, then decreased by -17bps to 64.49% in 2023, then fell by -2bps to 62.91% in 2024, then decreased by -16bps to 52.71% in 2025.
  • Its Gross Margin was 52.71% in Q3 2025, compared to 65.35% in Q2 2025 and 51.48% in Q1 2025.